Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
Date:8/2/2012

BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 2, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced financial results for its second quarter and six months ended June 30, 2012 and provided an overview of the clinical development activities of its two product candidates, custirsen and OGX-427.

Custirsen Clinical Development Highlights

  • The Company announced detailed plans for the ENSPIRIT trial, an international, randomized Phase 3 study in approximately 1,100 patients with advanced or metastatic non-small cell lung cancer (NSCLC). The trial will evaluate the potential survival benefit of combining custirsen with docetaxel as a second-line treatment in patients who have progressed after initial chemotherapy treatment has failed. Enrollment is planned to begin later this year and the trial will be managed by our development partner for custirsen, Teva Pharmaceuticals Industries LTD (TEVA).
  • Custirsen's primary registration Phase 3 study, SYNERGY, evaluating a survival benefit for custirsen plus first-line chemotherapy in patients with castrate-resistant prostate cancer (CRPC), remains on schedule and patient accrual is expected to be completed in the second half of 2012.
  • The Phase 3 AFFINITY study, evaluating a survival benefit for custirsen in combination with Jevtana® (cabazitaxel) as second-line chemotherapy in patients with CPRC, is expected to begin patient enrollment in the near future.
  • OGX-427 Clinical Development Highlights

  • Preliminary data from an investigator-sponsored Phase 2 clinical trial of OGX-427 in chemotherapy-naive patients with metastatic CRPC were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2012. Preliminary study results showed a higher number of patients without disease progression at 12 weeks and greater declines in prostate
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    2. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
    4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
    5. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
    6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
    7. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
    8. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
    9. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
    10. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
    11. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
    (Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
    (Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
    Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
    ... division of Wyeth (NYSE: WYE ), today ... has granted Fast Track designation,to the Company,s investigational ... is seeking a pediatric indication for,active immunization against ... serotypes included in the vaccine. The vaccine includes ...
    ... Targeting a Cure, WASHINGTON, May 28 ... join meso patients, caregivers,loved ones and advocates to ... at the Mesothelioma Applied Research Foundation,s,International Symposium on ... 28 at the Hyatt Regency on Capitol Hill, ...
    Cached Medicine Technology:Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 2Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 3Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 4International Symposium on Malignant Mesothelioma 2008 2
    (Date:7/10/2014)... Adults with dyslexia are more likely to report that ... people who don,t have the learning disorder, according to ... to 10 percent of people, causes problems with reading ... with this condition said they suffered physical abuse during ... dyslexia. "Even after accounting for age, race, sex ...
    (Date:7/10/2014)... News) -- Men who have a vasectomy may be ... study suggests. But the risk is comparatively small, ... the study said more research is needed to determine ... the study, Harvard researchers analyzed data from more than ... starting in 1986. During that time, 6,023 cases of ...
    (Date:7/10/2014)... that the "Mississippi Baby," believed to have been functionally ... detectable levels of the virus, the Elizabeth Glaser Pediatric ... remains hopeful that the scientific breakthrough that allowed the ... two years will continue to help researchers understand how ... , "Although we had high hopes that the child ...
    (Date:7/10/2014)... cells captured with a microchip-based device developed at the ... and the MGH Cancer Center can be cultured to ... In the July 11 issue of Science ... cells accurately reflect a tumor,s genetic mutation over time ... now can culture cells from the blood that represent ...
    (Date:7/10/2014)... "Mississippi baby" an infant seemingly cured of HIV that ... of HIV infection in The New England Journal of ... more than two years of not taking antiretroviral therapy without ... researchers involved in the case. , "Certainly, this ... the medical staff involved in the child,s care, and the ...
    Breaking Medicine News(10 mins):Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 3Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3
    ... , BREWER, Maine, Nov. 24 Thanks to an innovative ... Anthem Blue Cross and Blue Shield in Maine, some Anthem ... physician without leaving home. , As part of the ... and questions and communicate via email with their provider about ...
    ... pediatric cancer and hematology patients in medical rounds benefits ... a new Indiana University School of Medicine study. ... conducted, is now one of only a small number ... cancer and hematology patients the opportunity to join their ...
    ... ... available to discuss the recently proposed cosmetic surgery tax. , ... Arlington Heights, IL (Vocus) November 24, 2009 ... available to discuss the recently proposed cosmetic surgery tax., , ,WHAT: Some of ...
    ... strains have increased sevenfold, study finds, , TUESDAY, ... infections normally found in the community are increasingly ... that inpatients could become infected, new research says. ... sevenfold increase in the incidence of outpatients with ...
    ... New York personal injury ... attorney after a heavy metal piece falls off a plane and lands in a local Long ... New York, NY (PRWEB) ... recent occurrence as a reminder that everyone should have the number of a personal injury attorney ...
    ... ... seminar series, new ways to train doctors in providing proven, non-surgical relief to millions ... ... ) announced the first three 2010 Frozen Shoulder Syndrome Diagnosis & Treatment seminar ...
    Cached Medicine News:Health News:The Doctor Will See You Now. . .Online 2Health News:Involving family in medical rounds benefits both family and medical team 2Health News:Involving family in medical rounds benefits both family and medical team 3Health News:Involving family in medical rounds benefits both family and medical team 4Health News:Leading Plastic Surgery Experts Available to Discuss Proposed ,Cosmetic Surgery Tax 2Health News:MRSA Creeping Into Hospitals From the Outside 2Health News:MRSA Creeping Into Hospitals From the Outside 3Health News:A New York Neighborhood Gets Hit Hard When A Piece Breaks Off A Plane 2Health News:A New York Neighborhood Gets Hit Hard When A Piece Breaks Off A Plane 3Health News:OTZ Announces 2010 Frozen Shoulder Syndrome Seminar Schedule 2Health News:OTZ Announces 2010 Frozen Shoulder Syndrome Seminar Schedule 3
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: